BridgeMD
New treatment option for Metastatic Cancers
Official title Personalized Oncogenomics (POG) Program of British Columbia
ClinicalTrials.gov ID: NCT02155621
What this study is testing
What is Genome sequencing?
Genome sequencing is an investigational medicine, being studied as a potential treatment for metastatic cancers.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The genomic heterogeneity of cancers implies that to effectively use targeted therapies the investigators will need to assess each individual cancer and match it to a biologically relevant targeted therapy. The investigators will use full genome sequencing to try to identify cancer "drivers" and corresponding drugs that may inhibit these pathways.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 85
You may be able to join if
- Patients must agree to allow their archival specimens to be used and possibly completely depleted for these analyses.
- Willing and able to have a study-specific biopsy or resection of the tumour or metastatic site OR if there is adequate archival material available...
- Patients must understand and agree to provide a blood test (or other sample of normal DNA) for germline genomic analysis.
- ECOG PS 0 or 1.
- Age \>/= 18 years.
You likely can't join if
- Unable or unwilling to consent to the above tissue and blood requirements.
- Significant medical condition that in the opinion of the treating or consenting oncologist and/or the POG central office review team renders the...
- Unwilling or unable to provide treatment and outcome follow up information to the BC Cancer or affiliated investigators.
- Unwilling to receive medically actionable findings (germline and/or somatic).
See the full eligibility criteria
- Patients must agree to allow their archival specimens to be used and possibly completely depleted for these analyses.
- Willing and able to have a study-specific biopsy or resection of the tumour or metastatic site OR if there is adequate archival material available, either fresh frozen or FFPE (if specimen is thought to be adequate)...
- Patients must understand and agree to provide a blood test (or other sample of normal DNA) for germline genomic analysis.
- ECOG PS 0 or 1.
- Age \>/= 18 years.
- Estimated life expectancy \>/= 6 months and high likelihood of being clinically fit for a therapeutic clinical trial in 3-6 months.
- Measurable disease with RECIST v1.1 (or updated version).
- Adequate organ function.
- Patients must clearly understand that this data may be used to help guide treatment recommendations, including the avoidance of some therapeutic agents or the suggestion to use standard cytotoxic chemotherapy agents.
- Willingness to have their de-identified genomic and clinical data shared with national and international research collaborators and data sharing platforms (as detailed in the consent form).
- Willingness to be contacted for future studies based on the data that is generated by participation in POG; included in this is the anticipation that patient would be fit or a candidate for clinical trials.
- Unable or unwilling to consent to the above tissue and blood requirements.
- Significant medical condition that in the opinion of the treating or consenting oncologist and/or the POG central office review team renders the subject not suitable for participation. This includes the likelihood that...
- Unwilling or unable to provide treatment and outcome follow up information to the BC Cancer or affiliated investigators.
- Unwilling to receive medically actionable findings (germline and/or somatic).
The study team makes the final eligibility decision.
Where it's taking place
- Vancouver, British Columbia, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 85 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Vancouver, British Columbia, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.